JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, K. K.
Right arrow Articles by Worth, H. M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Chen, K. K.
Right arrow Articles by Worth, H. M.
Journal of Pharmacology And Experimental Therapeutics, Vol. 93, Issue 2, 156-160, 1948
Copyright © 1948 by American Society for Pharmacology and Experimental Therapeutics

OUABAGENIN

K. K. Chen 1, Robert C. Anderson 1, and Harold M. Worth 1

1 The Lilly Research Laboratories, Eli Lilly and Company, Indianapolis 6, Indiana

Ouabagenin is approximately one-half as active on the heart as ouabain in cats, and about one-third as active in frogs.

Ouabagenin is more effective than ouabain in causing vomiting of non-anesthetized cats, weight for weight. The emetic dose is therefore no measure of the cardiac activity when different compounds are compared.

Unlike digitoxigenin, ouabagenin and periplogenin do not cause convulsions in cats or frogs.

Submitted on February 9, 1948






Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1948 by the American Society for Pharmacology and Experimental Therapeutics.